NLS Pharmaceutics Overview
Get informed when a big investor buys or sells
+ Follow25.26
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
NLS Pharmaceutics (NLSP) currently reports a PEG ratio of 25.26. That is above the Healthcare sector average of 12.15. Use the charts on this page to explore NLS Pharmaceutics's PEG ratio history and peer comparisons.
NLS Pharmaceutics's PEG ratio of 25.26 is higher than the Healthcare sector average of 12.15. That is roughly 107.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates NLS Pharmaceutics's market price to a fundamental measure such as earnings, sales, or book value. At 25.26, NLSP can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 25.26, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 12.15. From there, open related valuation or income-statement pages for NLS Pharmaceutics, and consider following NLSP for alerts when major investors trade the stock.
NLS Pharmaceutics is classified in the Healthcare sector. On PEG ratio, it currently shows 25.26 versus a sector average near 12.15. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NLSP with unrelated industries.
